RT Journal Article
SR Electronic
T1 Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.01.21261397
DO 10.1101/2021.08.01.21261397
A1 O’Laughlin, Kelli N.
A1 Thompson, Matthew
A1 Hota, Bala
A1 Gottlieb, Michael
A1 Plumb, Ian D.
A1 Chang, Anna Marie
A1 Wisk, Lauren E.
A1 Hall, Aron J.
A1 Wang, Ralph C.
A1 Spatz, Erica S.
A1 Stephens, Kari A.
A1 Huebinger, Ryan M.
A1 McDonald, Samuel A.
A1 Venkatesh, Arjun
A1 Gentile, Nikki
A1 Slovis, Benjamin H.
A1 Hill, Mandy
A1 Saydah, Sharon
A1 Idris, Ahamed H.
A1 Rodriguez, Robert
A1 Krumholz, Harlan M.
A1 Elmore, Joann G.
A1 Weinstein, Robert A.
A1 Nichol, Graham
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/02/10/2021.08.01.21261397.abstract
AB BACKGROUND Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported outcomes with data from digital health records to understand predictors and impacts of SARS-CoV-2 infection.METHODS INSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of SARS-CoV-2 infection in eight regions across the US. Adults are eligible for enrollment if they are fluent in English or Spanish, reported symptoms suggestive of acute SARS-CoV-2 infection, and if they are within 42 days of having a SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test), regardless of test results. Recruitment occurs in-person, by phone or email, and through online advertisement. A secure online platform is used to facilitate the collation of consent-related materials, digital health records, and responses to self-administered surveys. Participants are followed for up to 18 months, with patient-reported outcomes collected every three months via survey and linked to concurrent digital health data; follow-up includes no in-person involvement. Our planned enrollment is 4,800 participants, including 2,400 SARS-CoV-2 positive and 2,400 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in individuals with and without infection. Patient-reported outcomes include self-reported health function and status, as well as clinical outcomes including health system encounters and new diagnoses.RESULTS Participating sites obtained institutional review board approval. Enrollment and follow-up are ongoing.CONCLUSIONS This study will characterize medium and long-term sequelae of SARS-CoV-2 infection among a diverse population, predictors of sequelae, and their relative risk compared to persons with similar symptomatology but without SARS-CoV-2 infection. These data may inform clinical interventions for individuals with sequelae of SARS-CoV-2 infection.Competing Interest StatementFINANCIAL DISCLOSURES The Innovative Support for Patients with SARS-COV-2 Infections (INSPIRE) Registry is funded by the Centers for Disease Control and Prevention (CDC, www.cdc.gov), National Center of Immunization and Respiratory Diseases (NCIRD) (contract number: 75D30120C08008; co-PIs Bala Hota, MD, and Robert A. Weinstein, MD). Partners from the CDC (IDP, AJH, SS) assisted with study design, the preparation of this protocol manuscript and the decision to publish this manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). No others sponsors or funders (other than the named authors) played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Additionally, I read the journal's policy and the authors of this manuscript have the following financial disclosures: JGE is an Editor for UpToDate on topics related to SARS-CoV-2 (https://www.uptodate.com). GN receives salary support from Leonard A Cobb~ Medic One Foundation (https://www.mediconefoundation.org/about/who-we-are/) via the University of Washington. He is a consultant to ZOLL Circulation Inc. (https://www.zoll.com/contact/careers-at-zoll/tms), ZOLL Medical Corporation (https://www.zoll.com/contact/careers-at-zoll/resuscitation), Cellphire Therapeutics Inc. (https://www.cellphire.com/) Kestra Medical Technologies (https://kestramedical.com/), Abiomed Inc. (https://www.abiomed.com/), CPR Therapeutics Inc. (https://www.cprtherapeutics.com/). HMK received expenses and/or personal fees from UnitedHealth (https://www.uhc.com/), Element Science (https://www.elementscience.com/), Aetna (https://www.aetna.com/), Facebook (https://www.facebook.com/), the Siegfried and Jensen Law Firm (https://www.siegfriedandjensen.com/), Arnold and Porter Law Firm (https://www.theworldlawgroup.com/member-firms/arnold-porter), Martin/Baughman Law Firm (https://www.martinbaughman.com/practice-areas/), and F-Prime (https://fprimecapital.com/). He is a co-founder of Refactor Health (https://www.refactorhealth.com/) and had grants and/or contracts from the Centers for Medicare & Medicaid Services (https://www.cms.gov/), the U.S. Food and Drug Administration (https://www.fda.gov/), and Johnson & Johnson (https://www.jnj.com/). MT provided consulting as a paid medical advisor to Visby Medical (https://www.visbymedical.com/) and Roche Molecular Diagnostics (https://diagnostics.roche.com/) which both produce laboratory tests for COVID-19. The authors not otherwise listed here have no financial disclosures COMPETING INTERESTS I read the journal's policy and the authors of this manuscript have the following competing interests: HMK is co-founder for Hugo Health; he is not employed by Hugo Health and he receives no salary support from Hugo Health. Hugo Health is a vendor to support INSPIRE study operations and is not the funder of this study or the subject of the investigation. This does not alter our adherence to PLOS ONE policies on sharing data and materials.Clinical TrialClinicalTrials.gov Identifier: NCT04610515Funding StatementThe study team is receiving financial support from the Centers for Disease Control and Prevention (CDC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval of this protocol has been obtained at each individual site including Rush University (protocol number: 20030902, approved 3/14/2020), Yale University (2000027976, approved 4/30/2020), the University of Washington (UW Human Subjects Division, STUDY00009920, approved 4/2/2020), Thomas Jefferson University (20p.1150, approved 1/21/2021), the University of Texas Southwestern Medical Center (STU 2020-1352, approved 2/3/2021), the University of Texas, Houston (HSC-MS-20-0981, approved 9/10/2020), the University of California, San Francisco (20-32222, approved 1/25/2021) and the University of California, Los Angeles (20-001683, approved 12/18/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe final data set will be accessible by study investigators, the CDC funders, and others as permitted contractually by the CDC.